[Dental and skeletal age in children with growth hormone deficiency treated with growth hormone--preliminary report].

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

The authors refer to the difference between chronological age and dental and skeletal age in children with growth hormone deficiency depending on the duration of treatment with growth hormone.

Why It Was Studied

Somatotrophic hypofunction (growth hormone deficiency--GHD) is one of the basic indications for treatment with growth hormone.

One of characteristics of this disease is a delay of bone age in comparison to calendar one.

Who Took Part

The abstract describes 6 children taking part.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

Twenty five patients with somatotrophic pituitary gland deficiency treated with growth hormone constituted research material.

The patients were divided into two groups depending on substitution therapy period length.

How the Study Was Run

All children were subject to clinical orthodontic examination--the kind of dental-occlusion defect was evaluated--and radiological diagnostics was conducted--orthopantomogram and cephalogram.

Matiegka and Lukasova clinical method was used for evaluation of dental age, while for radiological dental age evaluation the Demirjian's method.

Radiological evaluation, conducted basing on X-rays of palm and wrist and radiological atlas of Greulich-Pyle, was used for determination of skeletal age.

Schwarz and Steiner's analyses were used for cephalogram evaluation, considering the following angle parameters: SNA, SNB, ANB and G mandible angle.

What Was Measured

The subject headings attached to it are Age Determination by Skeleton, Age Determination by Teeth, Bone and Bones, Dwarfism, Pituitary, Growth Hormone, Malocclusion and Recombinant Proteins.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 6 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Pediatric endocrinology, diabetes, and metabolism), a journal based in Poland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.